New drug aims to shield heart muscle after major attack

NCT ID NCT06465303

Disease control Sponsor: ResoTher Pharma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental drug called RTP-026 in 96 adults who have had a severe type of heart attack (STEMI). Participants receive three short infusions of the drug or a placebo. The goal is to see if RTP-026 can reduce heart muscle damage, measured by blood markers. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: RTP-026 (a drug given as three 30-minute infusions)
What this could lead to: If it works, this could point toward a treatment that limits heart muscle damage after a severe heart attack, potentially improving recovery and reducing long-term heart failure risk.
What could go wrong: This is an early Phase 2 trial with only 96 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent for participation in the study has been obtained prior to initiating any study-specific procedures * Men between 18-85 years of age and post-menopausal women up to 85 years of age * Acute onset of chest pain of \< 12 hours duration * STEMI as characterized on ECG by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with a minimum of 1 mm concordant ST elevation or 1 mV ST elevation in the limb lead (II, III and aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior acute myocardial infarction (AMI) * Eligible for primary PCI * NLR in the range of 7-17 at hospital admission. In patients with chest pain lasting \> 3 - ≤ 6 hours at admission, the NLR should be in the range of 4.8-17 and for patients with chest pain lasting ≤ 3 hours at admission, the NLR should be in the range of 4.8-17, or the neutrophile count should be ≥ 9 x 10E9/L, irrespective of the lymphocyte count. For STEMI patients with an anterior or anterolateral infarction, the NLR should be ≥3. Exclusion Criteria: * Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry * Previous exposure to RTP-026 * Time from symptoms onset to primary PCI \> 12 hours * Previous CABG * Evidence of active malignant disease * Ongoing treatment with immune suppressive compounds * Any condition that, in the view of the investigator, would suggest that the patient is unable to comply with the study protocol and procedures * Known contraindications to CMR * ORBI Risk Score \> 12

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST elevation myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST elevation myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New drug aims to shield heart muscle after major attack

What the study statuses mean